129 related articles for article (PubMed ID: 38456705)
1. Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.
Korbal P; Wysocki J; Jackowska T; Kline M; Tamimi N; Drozd J; Lei L; Peng Y; Giardina PC; Gruber W; Scott D; Watson W
Pediatr Infect Dis J; 2024 Jun; 43(6):587-595. PubMed ID: 38456705
[TBL] [Abstract][Full Text] [Related]
2. A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
Senders S; Klein NP; Tamimi N; Thompson A; Baugher G; Trammel J; Peng Y; Giardina P; Scully IL; Pride M; Center KJ; Gruber WC; Scott DA; Watson W
Pediatr Infect Dis J; 2024 Jun; 43(6):596-603. PubMed ID: 38535409
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.
Haranaka M; Young Song J; Huang KC; de Solom R; Yamaji M; McElwee K; Kline M; Aizawa M; Peng Y; Scully I; Kogawara O; Gruber WC; Scott DA; Watson W
Vaccine; 2024 Feb; 42(5):1071-1077. PubMed ID: 38267330
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
[TBL] [Abstract][Full Text] [Related]
6. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Essink B; Sabharwal C; Cannon K; Frenck R; Lal H; Xu X; Sundaraiyer V; Peng Y; Moyer L; Pride MW; Scully IL; Jansen KU; Gruber WC; Scott DA; Watson W
Clin Infect Dis; 2022 Aug; 75(3):390-398. PubMed ID: 34940806
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
Senders S; Klein NP; Lamberth E; Thompson A; Drozd J; Trammel J; Peng Y; Giardina PC; Jansen KU; Gruber WC; Scott DA; Watson W
Pediatr Infect Dis J; 2021 Oct; 40(10):944-951. PubMed ID: 34525007
[TBL] [Abstract][Full Text] [Related]
8. A Phase 3, Single-arm Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Children 15 Months Through <18 Years of Age.
Meyer J; Silas P; Ouedraogo GL; McElwee K; Keep G; Trammel J; Peng Y; Scully IL; Gruber WC; Scott DA; Watson W
Pediatr Infect Dis J; 2024 Jun; 43(6):574-581. PubMed ID: 38502894
[TBL] [Abstract][Full Text] [Related]
9. A phase 3 randomized study to evaluate safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in healthy Japanese infants.
Ishihara Y; Fukazawa M; Enomoto S; de Solom R; Yamaji M; Kline M; Aizawa M; Peng Y; Kogawara O; Giardina PC; Tamimi N; Gruber WC; Watson W
Int J Infect Dis; 2024 Apr; 141():106942. PubMed ID: 38242195
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV; Thuluva S; Gunneri S; Yerroju V; Reddy Mogulla R; Thammireddy K; Paliwal P; Mahantshetty NS; Ravi MD; Prashanth S; Verma S; Narayan JP
Vaccine; 2024 May; 42(13):3157-3165. PubMed ID: 38637211
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China.
Zhu F; Hu Y; Li J; Ye Q; Young MM; Liang JZ; Gruber WC; Giardina PC; Scott DA
Pediatr Infect Dis J; 2019 Nov; 38(11):1150-1158. PubMed ID: 31626050
[TBL] [Abstract][Full Text] [Related]
13. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
Platt HL; Greenberg D; Tapiero B; Clifford RA; Klein NP; Hurley DC; Shekar T; Li J; Hurtado K; Su SC; Nolan KM; Acosta CJ; McFetridge RD; Bickham K; Musey LK;
Pediatr Infect Dis J; 2020 Aug; 39(8):763-770. PubMed ID: 32639460
[TBL] [Abstract][Full Text] [Related]
14. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.
Klein NP; Peyrani P; Yacisin K; Caldwell N; Xu X; Scully IL; Scott DA; Jansen KU; Gruber WC; Watson W
Vaccine; 2021 Sep; 39(38):5428-5435. PubMed ID: 34315611
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age.
Hurley D; Griffin C; Young M; Scott DA; Pride MW; Scully IL; Ginis J; Severs J; Jansen KU; Gruber WC; Watson W
Clin Infect Dis; 2021 Oct; 73(7):e1489-e1497. PubMed ID: 32716500
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China.
Zhu F; Hu Y; Li J; Ye Q; Young MM; Zhou X; Chen Z; Yan B; Liang JZ; Gruber WC; Giardina PC; Scott DA
Pediatr Infect Dis J; 2016 Sep; 35(9):999-1010. PubMed ID: 27254028
[TBL] [Abstract][Full Text] [Related]
18. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Martinon-Torres F; Wysocki J; Szenborn L; Carmona-Martinez A; Poder A; Dagan R; Richmond P; Gilbert C; Trudel MC; Flores S; Lupinacci R; McFetridge R; Wiedmann RT; Chen Q; Gerrits H; Banniettis N; Musey L; Bickham K; Kaminski J;
Vaccine; 2023 May; 41(21):3387-3398. PubMed ID: 37105892
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
[TBL] [Abstract][Full Text] [Related]
20. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil.
Weckx LY; Thompson A; Berezin EN; de Faria SM; da Cunha CA; Pride M; Patterson S; Gruber WC; Emini EA; Scott DA;
Vaccine; 2012 Dec; 30(52):7566-72. PubMed ID: 23099331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
